FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1922092456> ?p ?o ?g. }

• W1922092456 endingPage "1120" @default.
• W1922092456 startingPage "1113" @default.
• W1922092456 abstract "PURPOSE To assess the chemotherapy regimen of cisplatin, vinblastine, and hydrazine sulfate administered to patients with non-small-cell lung cancer (NSCLC) in a randomized, placebo-controlled double-blind phase III study. PATIENTS AND METHODS Between July 25, 1989 and February 1, 1991, 291 patients with stage IIIB or IV NSCLC and performance status 0 or 1 were randomized to receive cisplatin 100 mg/m2 intravenously (IV) every 28 days, vinblastine 5 mg/m2 IV per week times five, then every 2 weeks; and either hydrazine sulfate 60 mg three times per day orally or placebo. The concurrent use of corticosteroids, medroxyprogesterone, or other appetite stimulants was not permitted. Treatment groups were comparable for known prognostic variables. The primary end point of this study was survival; however, the influence of hydrazine sulfate on nutritional status, performance status, and quality of life was also assessed. RESULTS Analysis of 266 eligible patients showed a median survival duration of 7.78 months for the hydrazine sulfate-treated group compared with 7.70 months for the placebo-treated group (P = .65, log-rank). Objective response rates were similar for the two groups, with 4% complete responses, 20% partial responses, and 2% regressions in those treated with hydrazine sulfate; 3% complete responses, 23% partial responses, and 2% regressions in those who received placebo. The major toxicity was severe or life-threatening neutropenia, which occurred in 65% of hydrazine sulfate patients and 63% of placebo patients. There were no differences noted between the two groups in degree of anorexia, weight gain or loss, or overall nutritional status. Sensory and motor neuropathy occurred significantly more often in patients treated with hydrazine sulfate. Quality of life was significantly worse in patients who received hydrazine sulfate. CONCLUSION This study suggests no benefit from the addition of hydrazine sulfate to an effective cytotoxic regimen." @default.
• W1922092456 created "2016-06-24" @default.
• W1922092456 creator A5005344580 @default.
• W1922092456 creator A5011590188 @default.
• W1922092456 creator A5012302094 @default.
• W1922092456 creator A5014530221 @default.
• W1922092456 creator A5028502712 @default.
• W1922092456 creator A5034927366 @default.
• W1922092456 creator A5050036233 @default.
• W1922092456 creator A5075613250 @default.
• W1922092456 creator A5088998288 @default.
• W1922092456 date "1994-06-01" @default.
• W1922092456 modified "2023-10-06" @default.
• W1922092456 title "Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B." @default.
• W1922092456 cites W1580788756 @default.
• W1922092456 cites W1618675595 @default.
• W1922092456 cites W1659378382 @default.
• W1922092456 cites W1755983531 @default.
• W1922092456 cites W1803099259 @default.
• W1922092456 cites W1890140411 @default.
• W1922092456 cites W1922104747 @default.
• W1922092456 cites W1966351706 @default.
• W1922092456 cites W1975549289 @default.
• W1922092456 cites W1979300931 @default.
• W1922092456 cites W1980015319 @default.
• W1922092456 cites W1992676617 @default.
• W1922092456 cites W1998440426 @default.
• W1922092456 cites W2016847375 @default.
• W1922092456 cites W2053420961 @default.
• W1922092456 cites W2057763026 @default.
• W1922092456 cites W2068008235 @default.
• W1922092456 cites W2109539147 @default.
• W1922092456 cites W2170775996 @default.
• W1922092456 cites W2289202928 @default.
• W1922092456 cites W2415738154 @default.
• W1922092456 cites W2430835493 @default.
• W1922092456 cites W2098076970 @default.
• W1922092456 doi "https://doi.org/10.1200/jco.1994.12.6.1113" @default.
• W1922092456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8201372" @default.
• W1922092456 hasPublicationYear "1994" @default.
• W1922092456 type Work @default.
• W1922092456 sameAs 1922092456 @default.
• W1922092456 citedByCount "101" @default.
• W1922092456 countsByYear W19220924562013 @default.
• W1922092456 countsByYear W19220924562015 @default.
• W1922092456 countsByYear W19220924562018 @default.
• W1922092456 countsByYear W19220924562020 @default.
• W1922092456 countsByYear W19220924562021 @default.
• W1922092456 crossrefType "journal-article" @default.
• W1922092456 hasAuthorship W1922092456A5005344580 @default.
• W1922092456 hasAuthorship W1922092456A5011590188 @default.
• W1922092456 hasAuthorship W1922092456A5012302094 @default.
• W1922092456 hasAuthorship W1922092456A5014530221 @default.
• W1922092456 hasAuthorship W1922092456A5028502712 @default.
• W1922092456 hasAuthorship W1922092456A5034927366 @default.
• W1922092456 hasAuthorship W1922092456A5050036233 @default.
• W1922092456 hasAuthorship W1922092456A5075613250 @default.
• W1922092456 hasAuthorship W1922092456A5088998288 @default.
• W1922092456 hasConcept C126322002 @default.
• W1922092456 hasConcept C141071460 @default.
• W1922092456 hasConcept C142724271 @default.
• W1922092456 hasConcept C204787440 @default.
• W1922092456 hasConcept C27081682 @default.
• W1922092456 hasConcept C2776256026 @default.
• W1922092456 hasConcept C2776694085 @default.
• W1922092456 hasConcept C2777132456 @default.
• W1922092456 hasConcept C2781413609 @default.
• W1922092456 hasConcept C71924100 @default.
• W1922092456 hasConcept C90924648 @default.
• W1922092456 hasConceptScore W1922092456C126322002 @default.
• W1922092456 hasConceptScore W1922092456C141071460 @default.
• W1922092456 hasConceptScore W1922092456C142724271 @default.
• W1922092456 hasConceptScore W1922092456C204787440 @default.
• W1922092456 hasConceptScore W1922092456C27081682 @default.
• W1922092456 hasConceptScore W1922092456C2776256026 @default.
• W1922092456 hasConceptScore W1922092456C2776694085 @default.
• W1922092456 hasConceptScore W1922092456C2777132456 @default.
• W1922092456 hasConceptScore W1922092456C2781413609 @default.
• W1922092456 hasConceptScore W1922092456C71924100 @default.
• W1922092456 hasConceptScore W1922092456C90924648 @default.
• W1922092456 hasIssue "6" @default.
• W1922092456 hasLocation W19220924561 @default.
• W1922092456 hasLocation W19220924562 @default.
• W1922092456 hasOpenAccess W1922092456 @default.
• W1922092456 hasPrimaryLocation W19220924561 @default.
• W1922092456 hasRelatedWork W1519773982 @default.
• W1922092456 hasRelatedWork W1965964706 @default.
• W1922092456 hasRelatedWork W2098612596 @default.
• W1922092456 hasRelatedWork W2369324096 @default.
• W1922092456 hasRelatedWork W2376645157 @default.
• W1922092456 hasRelatedWork W2413365644 @default.
• W1922092456 hasRelatedWork W2433911436 @default.
• W1922092456 hasRelatedWork W243427647 @default.
• W1922092456 hasRelatedWork W36464137 @default.
• W1922092456 hasRelatedWork W4238093267 @default.
• W1922092456 hasVolume "12" @default.
• W1922092456 isParatext "false" @default.
• W1922092456 isRetracted "false" @default.

• next